• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Athersys wraps up enrollment for first phase of blood cancer study

Athersys wraps up enrollment for first phase of blood cancer study

January 6, 2011 By MedCity News

ATHX logo

Athersys Inc. (NSDQ:ATHX) has completed patient enrollment in the single-dose portion of a clinical trial that’s treating blood cancer patients with the company’s stem cell therapy.

The Phase 1 study involves dosing patients suffering from leukemia and other blood cancers with Athersys’ MultiStem, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other non-embryonic sources, according to the company. The cells have a drug-like effect, reducing inflammation, protecting damaged tissue and forming new blood vessels, and then are cleared from the body.

The patients involved in the study have received radiation therapy and a stem cell transplant from an outside donor, the company said. Such patients are typically at risk for graft-versus-host disease, which occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body.

MedCity News logo

The Food & Drug Administration last fall granted MultiStem orphan drug designation by for graft-versus-host disease. The orphan drug designation is important to Athersys because its benefits to the company include funding for certain clinical studies, study-design assistance, tax incentives and seven years of market exclusivity for the product upon regulatory approval.

The clinical trial is a multi-center dose escalation study aimed at evaluating the safety and maximum tolerated dose of MultiStem. The final patient in the single-dose arm was enrolled on Dec. 30. Athersys expects to complete enrollment in the multi-dose arm this year.

Athersys has exclusive development rights for oncology applications of MultiStem. The company has partnered with Pfizer for developing treatments for inflammatory bowel disease and Angiotech for cardiovascular disease treatments.

Filed Under: Business/Financial News, News Well, Stem Cells Tagged With: Athersys Inc.

More recent news

  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire
  • Medtronic wins CE mark for LigaSure sealing tech for Hugo surgical robot

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy